» Articles » PMID: 39200217

Applications of Multimodal Artificial Intelligence in Non-Hodgkin Lymphoma B Cells

Overview
Journal Biomedicines
Date 2024 Aug 29
PMID 39200217
Authors
Affiliations
Soon will be listed here.
Abstract

Given advancements in large-scale data and AI, integrating multimodal artificial intelligence into cancer research can enhance our understanding of tumor behavior by simultaneously processing diverse biomedical data types. In this review, we explore the potential of multimodal AI in comprehending B-cell non-Hodgkin lymphomas (B-NHLs). B-cell non-Hodgkin lymphomas (B-NHLs) represent a particular challenge in oncology due to tumor heterogeneity and the intricate ecosystem in which tumors develop. These complexities complicate diagnosis, prognosis, and therapy response, emphasizing the need to use sophisticated approaches to enhance personalized treatment strategies for better patient outcomes. Therefore, multimodal AI can be leveraged to synthesize critical information from available biomedical data such as clinical record, imaging, pathology and omics data, to picture the whole tumor. In this review, we first define various types of modalities, multimodal AI frameworks, and several applications in precision medicine. Then, we provide several examples of its usage in B-NHLs, for analyzing the complexity of the ecosystem, identifying immune biomarkers, optimizing therapy strategy, and its clinical applications. Lastly, we address the limitations and future directions of multimodal AI, highlighting the need to overcome these challenges for better clinical practice and application in healthcare.

References
1.
Foser S, Maiese K, Digumarthy S, Puig-Butille J, Rebhan C . Looking to the Future of Early Detection in Cancer: Liquid Biopsies, Imaging, and Artificial Intelligence. Clin Chem. 2024; 70(1):27-32. DOI: 10.1093/clinchem/hvad196. View

2.
Li D, Bledsoe J, Zeng Y, Liu W, Hu Y, Bi K . A deep learning diagnostic platform for diffuse large B-cell lymphoma with high accuracy across multiple hospitals. Nat Commun. 2020; 11(1):6004. PMC: 7691991. DOI: 10.1038/s41467-020-19817-3. View

3.
Wang Z, Liu Y, Niu X . Application of artificial intelligence for improving early detection and prediction of therapeutic outcomes for gastric cancer in the era of precision oncology. Semin Cancer Biol. 2023; 93:83-96. DOI: 10.1016/j.semcancer.2023.04.009. View

4.
Klempner S, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali S . Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist. 2019; 25(1):e147-e159. PMC: 6964127. DOI: 10.1634/theoncologist.2019-0244. View

5.
Carreras J, Hamoudi R, Nakamura N . Artificial intelligence and classification of mature lymphoid neoplasms. Explor Target Antitumor Ther. 2024; 5(2):332-348. PMC: 11090685. DOI: 10.37349/etat.2024.00221. View